SCHEMBL19904702

SCHEMBL19904702

CCCCOP(OCCCC)Oc1ccc(Cl)cc1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
HSD17B10 Q99714 1/20 0.40
KCNH2 Q12809 4/20 0.37
DRD2 P14416 2/20 0.37
DRD4 P21917 2/20 0.37
DRD3 P35462 2/20 0.37
KMT2A Q03164 4/20 0.36
MEN1 O00255 3/20 0.36
LTA4H P09960 2/20 0.35
POLB P06746 1/20 0.35
NR5A1 Q13285 1/20 0.34
TSHR P16473 1/20 0.34
ALDH1A1 P00352 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
PPARA Q07869 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2150640 0.83 MITF (0.39) SMN1; SMN2DRD2DRD4DRD3KMT2A
SCHEMBL445915 0.83 LTA4H (0.53) SMN1; SMN2KCNH2DRD2DRD3LTA4H
SCHEMBL10889093 0.82 HTR2A (0.39) KCNH2DRD2DRD4DRD3KMT2A
SCHEMBL19904703 0.81 MGLL (0.40) DRD2DRD4DRD3LTA4HNR5A1
SCHEMBL430999 0.79 LTA4H (0.53) SMN1; SMN2KCNH2DRD2DRD3LTA4H
SCHEMBL2150871 0.79 MITF (0.39) SMN1; SMN2DRD2DRD4DRD3KMT2A
SCHEMBL6461650 0.79 NR5A1 (0.43) SMN1; SMN2NPC1RAB9AHSD17B10DRD2
SCHEMBL8389043 0.79 NR5A1 (0.43) SMN1; SMN2NPC1RAB9AHSD17B10DRD2
SCHEMBL29033057 0.78 LTA4H (0.52) SMN1; SMN2KCNH2DRD2DRD4DRD3
SCHEMBL991869 0.78 LTA4H (0.53) SMN1; SMN2KCNH2DRD2DRD3LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024020507-A2 ORGANOPHOSPHOROUS COMPOUNDS AND USES THEREOF JAL THERAPEUTICS, LLC (US) 2024-01-25 WO disclosed
EP-2097428-B1 BUTYRYLCHOLINESTERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES MGP BIOTECHNOLOGIES INC (US) 2018-02-28 EP disclosed